<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893682</url>
  </required_header>
  <id_info>
    <org_study_id>APTO-CG-806-01</org_study_id>
    <nct_id>NCT03893682</nct_id>
  </id_info>
  <brief_title>A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas</brief_title>
  <official_title>A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptose Biosciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aptose Biosciences Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the safety, tolerability and effectiveness of Oral
      CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small
      lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to
      two or more lines of established therapy or for whom no other treatment options are
      available.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, Phase Ia/b dose escalation study of safety,
      pharmacodynamics, and pharmacokinetics of CG-806 in ascending cohorts (3+3 design) to
      determine the MTD or recommended dose in patients with relapsed or refractory CLL/SLL or
      Non-Hodgkin's Lymphoma patients. This is to be followed by a cohort expansion phase at the
      MTD or recommended oral dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events of CG-806</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>To determine the safety and tolerability of CG-806.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish a CG-806 dose that maintains a biologically active plasma concentration</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>To determine the dose of CG-806 given orally every 12 hours that maintains a biologically active plasma concentration over a period of 28 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish recommended dose for future development of CG-806</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>To establish the recommended Phase 2 dose (RP2D) of CG-806 for future clinical trials in patients with advanced CLL/SLL or NHL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including maximum plasma concentration (Cmax)</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including minimum plasma concentration (Cmin)</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including minimum plasma concentration (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including Area Under the Curve (AUC) Pharmacokinetic variables including Area Under the Curve (AUC Pharmacokinetic variables including Area Under the Curve (AUC</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including Area Under the Curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including volume of distribution</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including clearance</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including serum half-life</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including serum half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the antitumor activity of CG-806 using FDG PET-CT imaging evaluations</measure>
    <time_frame>Average 2 Cycles (8 weeks)</time_frame>
    <description>To assess the antitumor activity of CG-806 using FDG PET-CT imaging evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic biomarkers of drug effect including BTK activity</measure>
    <time_frame>Average 2 cycles (8 weeks)</time_frame>
    <description>Pharmacodynamic biomarkers of drug effect including BTK activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic biomarkers of drug effect including selected mRNA levels</measure>
    <time_frame>Average 2 cycles (8 weeks)</time_frame>
    <description>Pharmacodynamic biomarkers of drug effect including selected mRNA levels</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation and Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CG-806 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphomas (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 100 patients enrolled in the expansion cohort at the recommended dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG-806</intervention_name>
    <description>CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.</description>
    <arm_group_label>Dose Escalation and Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Life expectancy of at least 2 months

          -  ECOG Performance Status ≤ 2

          -  Patients must be able to swallow capsules

          -  Adequate hematologic parameters, unless cytopenias are disease caused

          -  Adequate renal, liver and cardiac function parameters

        Exclusion Criteria:

          -  Patients with GVHD requiring systemic immunosuppressive therapy

          -  Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and
             clinical significant disease related metabolic disorder

          -  Clinically significant intravascular coagulation

          -  Treatment with other investigational drugs within 14 days prior to first study
             treatment administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Bejar, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Aptose Biosciences Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rafael Bejar, MD, PhD</last_name>
    <phone>858-401-6852</phone>
    <email>RBejar@aptose.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cameron Vanderlinden</last_name>
      <phone>480-342-6065</phone>
      <email>Vanderlinden.Cameron@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Allison Rosenthal, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shenetra Walker, MSN/MHA</last_name>
      <phone>310-829-5471</phone>
      <phone_ext>16095</phone_ext>
      <email>skwalker@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Herbert Eradat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Care</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Mordy</last_name>
      <phone>831-375-4105</phone>
      <phone_ext>1081</phone_ext>
      <email>hmordy@pacificcancercare.com</email>
    </contact>
    <investigator>
      <last_name>Michael Z. Koontz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Kintzer</last_name>
      <phone>858-822-0743</phone>
      <email>ekintzer@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Reid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Clinical Oncology Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Pitsiouni, PhD,MSc,CCRA</last_name>
      <phone>858-939-5062</phone>
      <email>Maria.Pitsiouni@sharp.com</email>
    </contact>
    <investigator>
      <last_name>Kai Zu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Heathcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Lund</last_name>
      <phone>707-521-3803</phone>
      <email>Teresa.lund@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Jarrod P. Holmes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Gibson, RN, BSN, CRC</last_name>
      <phone>303-418-7639</phone>
      <email>Patricia.Gibson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>John M. Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Greenup</last_name>
      <phone>904-953-4088</phone>
      <email>Greenup.Julian@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>James Foran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Greenebaum Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janaiya Samuels, MS</last_name>
      <phone>410-328-2341</phone>
      <email>janaiya.samuels@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Seung Tae Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders a division of American Oncology Partners of Maryland, PA</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Bongiorno</last_name>
      <phone>301-571-2016</phone>
      <email>Natalie.bongiorno@aoncology.com</email>
    </contact>
    <investigator>
      <last_name>Victor Priego, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Wheeler, RN, BSN, OCN</last_name>
      <phone>774-455-4478</phone>
      <email>Jacqueline.Wheeler@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Jan Cerny, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Amundson</last_name>
      <phone>507-293-1933</phone>
      <email>Amundson.Michelle@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jose C Villasboas Bisneto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCL Health, St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Mclaughlin</last_name>
      <phone>406-238-6681</phone>
      <email>kelly.mclaughlin@sclhealth.org</email>
    </contact>
    <investigator>
      <last_name>Patrick Cobb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine K Rice, BS, MS, RN</last_name>
      <phone>973-971-5235</phone>
      <email>Christie.rice@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Mohamad Cherry, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manhattan Hematology Oncology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phenoia Browne</last_name>
      <phone>212-689-6791</phone>
      <phone_ext>228</phone_ext>
      <email>pbrowne@mhony.com</email>
    </contact>
    <investigator>
      <last_name>Alec S. Goldenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health - ITOR</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Roemmich, RN</last_name>
      <phone>864-455-6962</phone>
      <email>jill.roemmich@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Cull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Blood and Cancer Care Associates</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhwani Mehta, MS, BCMAS</last_name>
      <phone>803-329-7772</phone>
      <email>dmehta@cbcca.net</email>
    </contact>
    <investigator>
      <last_name>Niyati Nathwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin-Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Owens</last_name>
      <phone>512-421-4100</phone>
      <email>michelle.owens@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jason Melear, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catinna Mallett</last_name>
      <phone>214-370-1949</phone>
      <email>catinna.mallett@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Moshe Yair Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindi Schoenfeldt</last_name>
      <phone>817-413-1645</phone>
      <email>Cindi.Schoenfeldt@USOncology.com</email>
    </contact>
    <investigator>
      <last_name>Stephen L. Richey, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas, M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Montazari</last_name>
      <phone>713-792-5577</phone>
      <email>ejmontazari@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Felipe Samaniego, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Watkins</last_name>
      <phone>903-579-9899</phone>
      <email>penny.watkins@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Habte A. Yimer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen McClain</last_name>
      <phone>757-213-5658</phone>
      <email>Karen.McClain@USOncology.com</email>
    </contact>
    <investigator>
      <last_name>Paul Conkling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. - Compass Oncology</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Papenfuse, R.N.</last_name>
      <phone>360-449-6521</phone>
      <email>Susan.Papenfuse@USOncology.com</email>
    </contact>
    <investigator>
      <last_name>David Cosgrove, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral</keyword>
  <keyword>DLBCL</keyword>
  <keyword>PMBCL</keyword>
  <keyword>BCLU</keyword>
  <keyword>GZL</keyword>
  <keyword>MCL</keyword>
  <keyword>FL</keyword>
  <keyword>MZL</keyword>
  <keyword>WM</keyword>
  <keyword>LPL</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

